Literature DB >> 24643315

Adherence in the CAPRISA 004 tenofovir gel microbicide trial.

Leila Essop Mansoor1, Quarraisha Abdool Karim, Nonhlanhla Yende-Zuma, Kathleen M MacQueen, Cheryl Baxter, Bernadette T Madlala, Anneke Grobler, Salim S Abdool Karim.   

Abstract

High adherence is key to microbicide effectiveness. Here we provide a description of adherence interventions and the adherence rates achieved in the CAPRISA 004 Tenofovir gel trial. Adherence support for the before-and-after dosing strategy (BAT 24) was provided at enrolment and at each monthly study visit. This initially comprised individual counselling and was replaced midway by a structured theory-based adherence support program (ASP) based on motivational interviewing. The 889 women were followed for an average of 18 months and attended a total of 17,031 monthly visits. On average women reported five sex acts and returned 5.9 empty applicators per month. The adherence rate based on applicator count in relation to all reported sex acts was 72.2 % compared to the 82.0 % self-reported adherence during the last sex act. Adherence support activities, which achieve levels of adherence similar to or better than those achieved by the CAPRISA 004 ASP, will be critical to the success of future microbicide trials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24643315      PMCID: PMC4017080          DOI: 10.1007/s10461-014-0751-x

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  25 in total

Review 1.  Motivational interviewing in health care settings. Opportunities and limitations.

Authors:  K M Emmons; S Rollnick
Journal:  Am J Prev Med       Date:  2001-01       Impact factor: 5.043

2.  An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence.

Authors:  K R Amico; J Toro-Alfonso; J D Fisher
Journal:  AIDS Care       Date:  2005-08

3.  An information-motivation-behavioral skills model of adherence to antiretroviral therapy.

Authors:  Jeffrey D Fisher; William A Fisher; K Rivet Amico; Jennifer J Harman
Journal:  Health Psychol       Date:  2006-07       Impact factor: 4.267

4.  Involving behavioral scientists, health care providers, and HIV-infected patients as collaborators in theory-based HIV prevention and antiretroviral adherence interventions.

Authors:  Jeffrey D Fisher; Deborah H Cornman; Wynne E Norton; William A Fisher
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

5.  Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.

Authors:  Leila Essop Mansoor; Quarraisha Abdool Karim; Lise Werner; Bernadette Madlala; Nelisiwe Ngcobo; Deborah H Cornman; K Rivet Amico; Jeffrey Fisher; William A Fisher; Kathleen M Macqueen; Salim S Abdool Karim
Journal:  AIDS Behav       Date:  2014-05

6.  Behavioral risk for HIV infection among adults with a severe and persistent mental illness: patterns and psychological antecedents.

Authors:  M P Carey; K B Carey; L S Weinhardt; C M Gordon
Journal:  Community Ment Health J       Date:  1997-04

Review 7.  Antiretroviral therapy in sub-Saharan Africa: adherence lessons from tuberculosis and leprosy.

Authors:  S E Reid; C A Reid; S H Vermund
Journal:  Int J STD AIDS       Date:  2004-11       Impact factor: 1.359

8.  Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial.

Authors:  Sharon B Mannheimer; Edward Morse; John P Matts; Laurie Andrews; Carroll Child; Barry Schmetter; Gerald H Friedland
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

9.  Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials.

Authors:  Andrea R Wallace; Aaron Teitelbaum; Livia Wan; Maria Gloria Mulima; Laura Guichard; Stephanie Skoler; Stephanie Skiler; Hlengiwe Vilakazi; Fridda S Mapula; Jasmine Rossier; Sumen N Govender; Pekka Lahteenmaki; Robin A Maguire; David M Phillips
Journal:  Contraception       Date:  2007-05-11       Impact factor: 3.375

10.  Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

Authors:  Kenneth H Mayer; Lisa A Maslankowski; Fang Gai; Wafaa M El-Sadr; Jessica Justman; Antonia Kwiecien; Benoît Mâsse; Susan H Eshleman; Craig Hendrix; Kathleen Morrow; James F Rooney; Lydia Soto-Torres
Journal:  AIDS       Date:  2006-02-28       Impact factor: 4.177

View more
  11 in total

1.  Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.

Authors:  Ariane van der Straten; Ashley Mayo; Elizabeth R Brown; K Rivet Amico; Helen Cheng; Nicole Laborde; Jeanne Marrazzo; Kristine Torjesen
Journal:  AIDS Behav       Date:  2015-05

2.  Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.

Authors:  Leila Essop Mansoor; Quarraisha Abdool Karim; Lise Werner; Bernadette Madlala; Nelisiwe Ngcobo; Deborah H Cornman; K Rivet Amico; Jeffrey Fisher; William A Fisher; Kathleen M Macqueen; Salim S Abdool Karim
Journal:  AIDS Behav       Date:  2014-05

3.  Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.

Authors:  Kevin Melody; Sarah McBeth; Christopher Kline; Angela D M Kashuba; John W Mellors; Zandrea Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

4.  Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.

Authors:  Salim S Abdool Karim; Quarraisha Abdool Karim; Ayesha B M Kharsany; Cheryl Baxter; Anneke C Grobler; Lise Werner; Angela Kashuba; Leila E Mansoor; Natasha Samsunder; Adrian Mindel; Tanuja N Gengiah
Journal:  N Engl J Med       Date:  2015-08-06       Impact factor: 91.245

5.  A temperature-monitoring vaginal ring for measuring adherence.

Authors:  Peter Boyd; Delphine Desjardins; Sandeep Kumar; Susan M Fetherston; Roger Le-Grand; Nathalie Dereuddre-Bosquet; Berglind Helgadóttir; Ásgeir Bjarnason; Manjula Narasimhan; R Karl Malcolm
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

6.  Enhancing Interferon Regulatory Factor 7 Mediated Antiviral Responses and Decreasing Nuclear Factor Kappa B Expression Limit HIV-1 Replication in Cervical Tissues.

Authors:  Christiane Rollenhagen; Christiane Rollenhage; Sherrill L Macura; Melissa J Lathrop; Todd A Mackenzie; Gustavo F Doncel; Susana N Asin
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

7.  Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study.

Authors:  Sarah T Roberts; Jessica Haberer; Connie Celum; Nelly Mugo; Norma C Ware; Craig R Cohen; Jordan W Tappero; James Kiarie; Allan Ronald; Andrew Mujugira; Elioda Tumwesigye; Edwin Were; Elizabeth Irungu; Jared M Baeten
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

8.  Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides.

Authors:  Cristina Tintori; Giulia Iovenitti; Elisa Rita Ceresola; Roberto Ferrarese; Claudio Zamperini; Annalaura Brai; Giulio Poli; Elena Dreassi; Valeria Cagno; David Lembo; Filippo Canducci; Maurizio Botta
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

Review 9.  The promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform prep interventions among female sex workers.

Authors:  Jennifer L Syvertsen; Angela M Robertson Bazzi; Andrew Scheibe; Sylvia Adebajo; Steffanie A Strathdee; Wendee M Wechsberg
Journal:  Afr J Reprod Health       Date:  2014-09

10.  The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.

Authors:  Grant Murewanhema; Moffat Malisheni; Noah Fongwen Takah
Journal:  Pan Afr Med J       Date:  2021-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.